Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
HAMPTON, N.J., Feb. 18, 2016 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2015 financial results on Thursday, February 25, 2016 before the U.S. financial markets open. Celldex executives will host a conference call at 8:00 a.m. EST on the same day to discuss 2015 financial and business results and to provide an update on key 2016 objectives.
The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 50465153.
A replay of the call will be available approximately two hours after the live call concludes through March 3, 2016. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 50465153. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
